Abstract
Cardinal Health will report fiscal Q4 2026 results on August 11, 2026 Pre-MKt; this preview summarizes consensus expectations for revenue, margins, net income, and adjusted EPS, alongside the quarter’s key business drivers and prevailing analyst sentiment.
Market Forecast
For the current quarter, the market projects revenue of 65.03 billion US dollars, implying year-over-year growth of 6.83%, with estimated EBIT of 819.89 million US dollars, adjusted EPS of 2.42 (up 18.76% year over year), and implied margin expansion versus last year; the company’s prior report frames a mid-single-digit revenue growth trajectory with improving profitability. Consensus implies gross profit and net profit margin stability to slight improvement, given the estimated EBIT growth of 12.10% and EPS growth outpacing revenue. The core Pharmaceutical and Specialty Solutions business remains the primary engine, supported by brand-to-generic conversions and specialty volume; the Medical segment outlook suggests gradual recovery. Specialty distribution and services are seen as the largest growth opportunity, with revenue scale embedded within the Pharmaceutical and Specialty Solutions line and outpacing the consolidated growth rate year over year.
Last Quarter Review
In the previous quarter, Cardinal Health delivered revenue of 60.94 billion US dollars (up 11.05% year over year), a gross profit margin of 4.10%, net income attributable to shareholders of 399.00 million US dollars with a net margin of 0.65%, and adjusted EPS of 3.17 (up 34.89% year over year). A notable highlight was better-than-expected profitability with EBIT of 956.00 million US dollars, reflecting disciplined cost execution and favorable mix. By business, the Pharmaceutical and Specialty Solutions unit generated 56.11 billion US dollars, the Global Medical Products and Distribution unit contributed 3.15 billion US dollars, and Other reported 1.71 billion US dollars, underscoring the outsized weight of the core pharma distribution franchise.
Current Quarter Outlook (with major analytical insights)
Main business: Pharmaceutical and Specialty Solutions
The Pharmaceutical and Specialty Solutions segment accounts for the vast majority of consolidated revenue and earnings, and consensus indicates it will again anchor growth this quarter. Volume growth from specialty therapies and continued generic program contributions are poised to offset price competition on branded distribution spreads. The margin profile remains sensitive to customer and product mix, but EBIT growth tracking above revenue suggests that purchasing scale and fee-for-service economics could support incremental margin leverage. Watch for commentary on biosimilar adoption rates in oncology and immunology categories, which can boost throughput and operating income even with modest per-unit margins. Management’s execution on manufacturer contracting and independent pharmacy support programs will also influence near-term profitability.
Most promising business: Specialty distribution and services
Within the broader Pharmaceutical and Specialty Solutions umbrella, specialty distribution and related services continue to present the greatest incremental growth potential. The expected revenue contribution remains embedded in the segment’s 56.11 billion US dollars last quarter base, and growth is modeled to exceed the enterprise’s 6.83% revenue trajectory this quarter as oncology, rheumatology, and immunology volumes expand. Margin accretion can come from higher-value services such as hub support, patient access programs, and data-enabled manufacturer services. A sustained biosimilar ramp, particularly in oncology supportive care and autoimmune categories, may enhance unit economics while broadening the customer base. Competitive dynamics with national peers remain a risk, yet contract wins and share gains in key therapeutic areas could keep specialty volumes resilient.
Key stock price drivers this quarter
The stock’s near-term reaction will likely hinge on the spread between revenue growth and adjusted EPS growth. With EPS projected to rise 18.76% on 6.83% revenue growth, investors will look for confirmation of operating leverage, especially in distribution fees and procurement benefits. Any updates on capital allocation—such as buybacks against a rising EPS base—could amplify per-share growth. On the risk side, price competition in core distribution and any inventory normalization in medical products may compress gross margins if volumes disappoint. Also critical will be management’s guidance for fiscal 2027, particularly cash conversion and working capital cadence, which can affect valuation multiples.
Analyst Opinions
Bullish views dominate recent commentary, with a majority of sell-side and institutional perspectives emphasizing improving earnings quality and operating leverage. Well-known institutions highlight consistent execution in the Pharmaceutical and Specialty Solutions segment and a recovery trajectory in Medical, pointing to the gap between revenue and EPS growth as evidence of structural margin progress. Analysts underline that consensus revenue growth of 6.83% alongside a forecast 12.10% EBIT increase and 18.76% EPS expansion reflects operational efficiency and disciplined cost control. The bull case expects sustained specialty momentum, continued generic program benefits, and prudent capital deployment to support mid-teens EPS growth trends. Investors are expected to focus on whether management reiterates or tightens full-year margin improvement targets and on the visibility of biosimilar-driven throughput gains.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments